Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310116 | 1.00 | KDR (0.54) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL28417878 | 0.88 | KDR (0.49) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL27437769 | 0.85 | KDR (0.56) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL28906323 | 0.84 | KDR (0.54) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL11365957 | 0.84 | KDR (0.54) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL6029569 | 0.81 | DHODH (0.51) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL5074093 | 0.81 | KDM4E (0.53) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL4623053 | 0.81 | ESR1 (0.53) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL3802643 | 0.80 | BRD4 (0.42) | KDRCHEK1KDM4EALDH1A1MAPT | |
| SCHEMBL8734933 | 0.80 | KDM4E (0.57) | KDRCHEK1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | ESANEX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | ESANEX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | ESANEX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| CN-107428740-A | Indazolyl-and indolyl-benzamide derivatives | 埃萨内克斯股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107428740-A | Indazolyl-and indolyl-benzamide derivatives | 埃萨内克斯股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20160075662-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2016-03-17 | — | — | US | disclosed |
| CN-102372659-A | Indolebenzamide derivatives and medicinal applications thereof | UNIV FUDAN | 2012-03-14 | — | — | CN | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| CN-101535253-A | Indole and benzofuran 2-carboxamide derivatives | INDOLE AND BENZOFURAN 2 CARBOX (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1283638-C | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2006-11-08 | — | — | CN | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| CN-1589270-A | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | IDO2, MKI67, IDO1 | KDR 10/4885CHEK1 1951/4885KDM4E 1757/4885 |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | IDO2, MKI67, IDO1 | KDR 10/4885CHEK1 1951/4885KDM4E 1757/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | KDR 4141/4885CHEK1 4712/4885KDM4E 2869/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | KDR 4141/4885CHEK1 4712/4885KDM4E 2869/4885 |
| US-20160075662-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | IDO2, MKI67, IDO1 | KDR 10/4885CHEK1 1951/4885KDM4E 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.